Ilmarinen Mutual Pension Insurance Co lessened its stake in shares of Synopsys, Inc. (NASDAQ:SNPS – Free Report) by 20.6% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 18,511 shares of the semiconductor company’s stock after selling 4,809 shares during the quarter. Ilmarinen Mutual Pension Insurance Co’s holdings in Synopsys were worth $8,051,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Whittier Trust Co. raised its holdings in Synopsys by 2.9% during the 3rd quarter. Whittier Trust Co. now owns 847 shares of the semiconductor company’s stock valued at $368,000 after buying an additional 24 shares during the last quarter. Elevation Wealth Partners LLC grew its holdings in Synopsys by 96.4% in the 2nd quarter. Elevation Wealth Partners LLC now owns 55 shares of the semiconductor company’s stock worth $25,000 after acquiring an additional 27 shares during the last quarter. North Dakota State Investment Board grew its holdings in Synopsys by 0.5% in the 3rd quarter. North Dakota State Investment Board now owns 5,706 shares of the semiconductor company’s stock worth $2,482,000 after acquiring an additional 29 shares during the last quarter. Oak Grove Capital LLC grew its holdings in Synopsys by 1.1% in the 3rd quarter. Oak Grove Capital LLC now owns 2,898 shares of the semiconductor company’s stock worth $1,260,000 after acquiring an additional 32 shares during the last quarter. Finally, Kintegral Advisory LLC increased its position in shares of Synopsys by 0.6% in the third quarter. Kintegral Advisory LLC now owns 5,812 shares of the semiconductor company’s stock valued at $2,528,000 after acquiring an additional 32 shares during the period. Institutional investors own 85.47% of the company’s stock.
Insider Activity at Synopsys
In other Synopsys news, CEO Sassine Ghazi sold 14,604 shares of Synopsys stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $374.88, for a total transaction of $5,474,747.52. Following the sale, the chief executive officer directly owned 76,865 shares of the company’s stock, valued at approximately $28,815,151.20. The trade was a 15.97% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Aart de Geus sold 25,000 shares of the stock in a transaction on Monday, August 31st. The stock was sold at an average price of $441.76, for a total value of $11,044,000.00. Following the completion of the sale, the insider directly owned 120,421 shares in the company, valued at approximately $53,197,180.96. This represents a 17.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 117,163 shares of company stock worth $51,366,457 over the last ninety days. Corporate insiders own 0.56% of the company’s stock.
Top Synopsys Stories
Investors following SNPS have been watching these stories:
- Positive Sentiment: Synopsys-backed Ansys is supporting an integration between Instem’s toxicology tools and its simulation platform, extending the company’s reach into packaging safety and materials-risk workflows. This could broaden use of its simulation ecosystem, though the financial impact is not specified. Synopsys broadens platform reach
- Neutral Sentiment: Synopsys is described as having stronger forward growth and a lower forward valuation multiple than Cadence, but Cadence is credited with a stronger balance sheet and returns on capital. Synopsys vs. Cadence
- Negative Sentiment: A valuation analysis argues SNPS may be about 17% overvalued despite improving guidance and business performance, raising questions about whether future cash generation justifies the share price. Synopsys may be overvalued
Analyst Ratings Changes
Several equities analysts have recently commented on SNPS shares. KeyCorp upped their price objective on shares of Synopsys from $600.00 to $605.00 and gave the company an “overweight” rating in a research note on Thursday, October 1st. Rothschild & Co Redburn cut their target price on Synopsys from $560.00 to $550.00 and set a “buy” rating on the stock in a research note on Wednesday, September 23rd. Barclays initiated coverage on Synopsys in a report on Thursday. They set an “overweight” rating and a $640.00 price target on the stock. JPMorgan Chase & Co. reduced their price target on Synopsys from $650.00 to $600.00 in a report on Thursday, August 27th. Finally, Benchmark reaffirmed a “buy” rating and set a $570.00 price target on shares of Synopsys in a research report on Thursday, August 27th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $577.71.
Read Our Latest Analysis on Synopsys
Synopsys Stock Performance
NASDAQ:SNPS opened at $396.55 on Friday. The stock has a market cap of $76.00 billion, a P/E ratio of 70.06, a price-to-earnings-growth ratio of 1.40 and a beta of 1.18. The firm’s fifty day simple moving average is $448.46 and its 200 day simple moving average is $440.14. Synopsys, Inc. has a twelve month low of $362.55 and a twelve month high of $539.48. The company has a quick ratio of 1.24, a current ratio of 1.34 and a debt-to-equity ratio of 0.29.
Synopsys (NASDAQ:SNPS – Get Free Report) last issued its quarterly earnings data on Wednesday, August 26th. The semiconductor company reported $3.91 EPS for the quarter, topping the consensus estimate of $3.67 by $0.24. Synopsys had a net margin of 11.43% and a return on equity of 6.24%. The business had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.44 billion. During the same period in the prior year, the business earned $3.39 EPS. The company’s revenue for the quarter was up 42.4% on a year-over-year basis. Synopsys has set its Q4 2026 guidance at 4.100-4.160 EPS and its FY 2026 guidance at 15.040-15.100 EPS. As a group, research analysts predict that Synopsys, Inc. will post 11.01 EPS for the current year.
Synopsys announced that its Board of Directors has approved a stock buyback plan on Monday, October 5th that permits the company to buy back $1 billion in shares. This buyback authorization permits the semiconductor company to purchase up to 1.1% of its stock through open market purchases. Share buyback plans are generally an indication that the company’s board of directors believes its shares are undervalued.
Synopsys Company Profile
Synopsys, Inc. develops software, semiconductor intellectual property (IP) and services used to design and verify electronic systems. Its electronic design automation (EDA) tools help customers create, simulate, test and validate chips and other complex electronic products, while its IP portfolio provides reusable building blocks for semiconductor designs. The company also offers software security and quality tools that help developers identify vulnerabilities and assess applications throughout the software development process.
Read More
- Five stocks we like better than Synopsys
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Receive News & Ratings for Synopsys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synopsys and related companies with MarketBeat.com's FREE daily email newsletter.
